Kintor Pharmaceutical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Kintor Pharmaceutical's earnings have been declining at an average annual rate of -22.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 85.7% per year.
Anahtar bilgiler
-22.2%
Kazanç büyüme oranı
-12.9%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 11.0% |
| Gelir büyüme oranı | -85.7% |
| Özkaynak getirisi | -235.0% |
| Net Marj | n/a |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?
Oct 07
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Nov 16Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Apr 28Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Dec 06Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?
Sep 01Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings
Feb 17What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?
Dec 23
Gelir ve Gider Dağılımı
Kintor Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -920 | 72 | 814 |
| 31 Mar 24 | 0 | -991 | 84 | 876 |
| 31 Dec 23 | 0 | -1,061 | 96 | 939 |
| 30 Sep 23 | 0 | -854 | 116 | 735 |
| 30 Jun 23 | 0 | -648 | 136 | 532 |
| 31 Mar 23 | 0 | -801 | 144 | 680 |
| 31 Dec 22 | 0 | -954 | 153 | 828 |
| 30 Sep 22 | 17 | -995 | 145 | 887 |
| 30 Jun 22 | 34 | -1,035 | 138 | 947 |
| 31 Mar 22 | 34 | -938 | 128 | 857 |
| 31 Dec 21 | 34 | -842 | 118 | 768 |
| 30 Sep 21 | 17 | -740 | 116 | 615 |
| 30 Jun 21 | 0 | -639 | 114 | 463 |
| 31 Mar 21 | 0 | -573 | 100 | 396 |
| 31 Dec 20 | 0 | -508 | 86 | 329 |
| 30 Sep 20 | 0 | -419 | 63 | 301 |
| 30 Jun 20 | 0 | -330 | 39 | 273 |
| 31 Mar 20 | 0 | -281 | 30 | 243 |
| 31 Dec 19 | 0 | -233 | 21 | 214 |
| 31 Dec 18 | 1 | -108 | 24 | 93 |
| 31 Dec 17 | 0 | -46 | 50 | 0 |
| 30 Sep 17 | 0 | -41 | 44 | 0 |
| 30 Jun 17 | 0 | -35 | 39 | 0 |
| 31 Mar 17 | 1 | -45 | 49 | 0 |
| 31 Dec 16 | 1 | -54 | 60 | 0 |
| 31 Dec 15 | 0 | -11 | 14 | 0 |
Kaliteli Kazançlar: 9939 is currently unprofitable.
Büyüyen Kar Marjı: 9939 is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 9939 is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Büyüme Hızlandırma: Unable to compare 9939's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: 9939 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Özkaynak Getirisi
Yüksek ROE: 9939 has a negative Return on Equity (-235%), as it is currently unprofitable.